0.70
+0.0544(+8.45%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.77 |
| Day High | 0.87 |
| Day Low | 0.56 |
| 52-Week High | 4.19 |
| 52-Week Low | 0.46 |
| Volume | 61.08M |
| Average Volume | 482,673 |
| Market Cap | 40.19M |
| PE | -0.71 |
| EPS | -0.98 |
| Moving Average 50 Days | 0.64 |
| Moving Average 200 Days | 1.46 |
| Change | 0.05 |
If you invested $1000 in Rani Therapeutics Holdings, Inc. (RANI) since IPO date, it would be worth $63.49 as of July 15, 2025 at a share price of $0.698. Whereas If you bought $1000 worth of Rani Therapeutics Holdings, Inc. (RANI) shares 3 years ago, it would be worth $57.53 as of July 15, 2025 at a share price of $0.698.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
GlobeNewswire Inc.
Yesterday at 9:00 AM GMT
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that
Rani Therapeutics Announces Research Agreement with Chugai
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
GlobeNewswire Inc.
Mar 26, 2025 8:05 PM GMT
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated comparable weight loss with less v